Analyst All-Stars
Take advantage of Wall Street's collective wisdom with this portfolio of top-rated stocks. These companies have earned strong 'Buy' ratings from respected financial analysts because of their solid fundamentals and potential for market outperformance.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Broadcom Inc.
AVGO
Current price
$294.91
A semiconductor and software giant, it is consistently rated 'Buy' by analysts due to its market leadership and integral role in global technology inf...
A semiconductor and software giant, it is consistently rated 'Buy' by analysts due to its market leadership and integral role in global technology infrastructure.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
This collection harnesses the collective intelligence of Wall Street's most trusted analysts. By focusing on companies with strong consensus 'Buy' ratings, we're leveraging deep institutional research to identify businesses with robust fundamentals and clear paths to growth.
What You Need to Know
These stocks span diverse industries from technology to finance, offering built-in diversification. Each company has passed rigorous professional scrutiny of its financial health, competitive position, and management quality, creating a growth-oriented portfolio backed by expert validation.
Why These Stocks
Each company was selected because it earned a 'Strong Buy' or 'Buy' rating from a significant majority of analysts covering it. In a market overwhelmed with information, this expert consensus acts as a critical filter for identifying quality stocks with higher probability of outperformance.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+172.75%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 172.75% over the next year.
Stocks Rated Buy by Analysts
15 of 15 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 4.5% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
Wall Street's Best Thinking
These stocks represent the distilled wisdom of countless hours of professional research. When top analysts agree on a company's potential, it's worth paying attention.
Professionally Vetted Winners
Feel more confident knowing these companies have passed through rigorous scrutiny. Every stock has been thoroughly analyzed for financial health, competitive positioning, and growth potential.
Hidden Gems Across Industries
Discover opportunities you might have missed. This diverse collection spans tech innovators, healthcare pioneers, and financial leaders - all backed by professional conviction.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Beyond The App Store: Europe's New Rules
Following regulatory pressure from the European Union, Google has revised its Play Store rules to permit alternative payment systems. This change creates a new investment opportunity in companies poised to benefit from a more open mobile app ecosystem.
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Frequently Asked Questions
Everything you need to know about the product and billing.